1. any vaccination/immunization within 30 days before the enrollment; 2. steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 3. immunosuppressors therapy finished within 3 months before the enrollment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrollment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day 8. neoplasms in the medical history. 9. donated blood or plasma (450+ ml) within 2 months before the enrollment 10. splenectomy in the medical history 11. neutropenia (absolute neutrophil count \<1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin \<80 g/l), immunodeficiency in the medical history within 6 months before the enrollment 12. active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b or c 13. anorexia, protein deficiency of any origin 14. big-size tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the study drug/placebo administration 15. alcohol or drug addiction in the medical history 16. participation in any other interventional clinical trial. 17. any other condition that the study physician considers as a barrier to the trial completion as per the protocol 18. study center staff and other employees directly involved in the trial and their families.

1. any vaccination/immunization within 30 days before the enrollment; 2. steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 3. immunosuppressors therapy finished within 3 months before the enrollment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrollment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day 8. neoplasms in the medical history. 9. donated blood or plasma (450+ ml) within 2 months before the enrollment 10. splenectomy in the medical history 11. neutropenia (absolute neutrophil count \<1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin \<80 g/l), immunodeficiency in the medical history within 6 months before the enrollment 12. active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b or c 13. anorexia, protein deficiency of any origin 14. big-size tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the study drug/placebo administration 15. alcohol or drug addiction in the medical history 16. participation in any other interventional clinical trial. 17. any other condition that the study physician considers as a barrier to the trial completion as per the protocol 18. study center staff and other employees directly involved in the trial and their families.

any vaccination/immunization within 30 days before the enrollment; steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. immunosuppressors therapy finished within 3 months before the enrollment pregnancy or breast-feeding acute coronary syndrome or stroke suffered less than one year before the enrollment tuberculosis, chronic systemic infections drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day neoplasms in the medical history. donated blood or plasma (450+ ml) within 2 months before the enrollment splenectomy in the medical history neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b or c anorexia, protein deficiency of any origin big-size tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the study drug/placebo administration alcohol or drug addiction in the medical history participation in any other interventional clinical trial. any other condition that the study physician considers as a barrier to the trial completion as per the protocol study center staff and other employees directly involved in the trial and their families.

any vaccination/immunization within 30 days before the enrollment; steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. immunosuppressors therapy finished within 3 months before the enrollment pregnancy or breast-feeding acute coronary syndrome or stroke suffered less than one year before the enrollment tuberculosis, chronic systemic infections drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day neoplasms in the medical history. donated blood or plasma (450+ ml) within 2 months before the enrollment splenectomy in the medical history neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b or c anorexia, protein deficiency of any origin big-size tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the study drug/placebo administration alcohol or drug addiction in the medical history participation in any other interventional clinical trial. any other condition that the study physician considers as a barrier to the trial completion as per the protocol study center staff and other employees directly involved in the trial and their families.

1. any vaccination/immunization within 30 days before the enrollment; 2. steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 3. immunosuppressors therapy finished within 3 months before the enrollment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrollment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day 8. neoplasms in the medical history. 9. donated blood or plasma (450+ ml) within 2 months before the enrollment 10. splenectomy in the medical history 11. neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment 12. active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b or c 13. anorexia, protein deficiency of any origin 14. big-size tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the study drug/placebo administration 15. alcohol or drug addiction in the medical history 16. participation in any other interventional clinical trial. 17. any other condition that the study physician considers as a barrier to the trial completion as per the protocol 18. study center staff and other employees directly involved in the trial and their families.

1. any vaccination/immunization within 30 days before the enrollment; 2. steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment. 3. immunosuppressors therapy finished within 3 months before the enrollment 4. pregnancy or breast-feeding 5. acute coronary syndrome or stroke suffered less than one year before the enrollment 6. tuberculosis, chronic systemic infections 7. drug allergy (anaphylactic shock, quincke's edema, polymorphic exudative eczema, atopy, serum disease), hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study drug components, acute exacerbation of allergic diseases on the enrollment day 8. neoplasms in the medical history. 9. donated blood or plasma (450+ ml) within 2 months before the enrollment 10. splenectomy in the medical history 11. neutropenia (absolute neutrophil count <1,000 mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/l), immunodeficiency in the medical history within 6 months before the enrollment 12. active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis b or c 13. anorexia, protein deficiency of any origin 14. big-size tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the study drug/placebo administration 15. alcohol or drug addiction in the medical history 16. participation in any other interventional clinical trial. 17. any other condition that the study physician considers as a barrier to the trial completion as per the protocol 18. study center staff and other employees directly involved in the trial and their families.